Alector, Inc.
NASDAQ:ALECBiotechnology
+$0.08 today
- Market cap
- $382.61M
- Beta
- 0.59
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.13
Volume 2.13M
Average 0.65M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Alector, Inc.
NASDAQ:ALEC
Intrinsic Alpha fair value
Locked
Current Price
$2.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -46.0% | -11.1% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -46.0% over three years. Forward estimates point to Revenue at -11.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Vor Biopharma Inc. NASDAQ:VOR | $1.05B | $19.42 | Not rated | -0.0 | +128.01% |
Opus Genetics, Inc. NASDAQ:IRD | $331.12M | $3.98 | Not rated | -33.0 | +110.75% |
PepGen Inc. NASDAQ:PEPG | $301.98M | $4.36 | Not rated | -1.6 | -30.74% |
Fate Therapeutics, Inc. NASDAQ:FATE | $149.20M | $1.28 | Not rated | -1.8 | +0.00% |
Molecular Partners AG NASDAQ:MOLN | $112.71M | $2.94 | Not rated | -2.0 | -36.40% |
Nkarta, Inc. NASDAQ:NKTX | $85.23M | $1.19 | Not rated | -2.0 | -35.75% |
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | $69.86M | $3.39 | Not rated | -1.3 | -76.78% |
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | $15.48M | $0.21 | Not rated | -1.3 | +47.74% |
Continue the stock analysis
Jump to another research area for this company.